AI Analysis
AI-generated analysis. Always verify with the original filing.
Centessa Pharmaceuticals generated $15.0 million in revenue during FY2025, marking its first revenue contribution, while net losses narrowed year-over-year due to lower R&D expenses and non-operating income from foreign currency fluctuations.
Key Takeaways
1Revenue was $15.0M ($0.00): First-time revenue recognition reflects progress in commercialization efforts or partnership milestones.
2Operating Income was -$207.7M (-3.3%): Slight year-over-year deterioration driven by rising personnel and professional fees despite cost management in development programs.
3Eps was $-1.46 (29.1%): Loss per share decreased significantly as net loss improved and share count remained stable.
4Free Cash Flow was -$194.2M: Cash burn increased due to higher operating cash outflows, partially offset by lower capital spending growth.